Nasdaq

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Seeking Alpha

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
Nasdaq

GeneDx expands access to exome testing for pediatric epilepsy patients

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
Seeking Alpha

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and ...
Business Wire

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GAITHERSBURG, Md.--(BUSINESS ...

GeneDx Q4 Earnings Call Highlights

GeneDx (NASDAQ:WGS) reported fourth-quarter revenue of $121 million, bringing full-year 2025 revenue to $428 million, as management highlighted accelerating exome and genome testing demand and ...